COVID vaccine protected kids from long COVID
Peer-Reviewed Publication
Updates every hour. Last Updated: 26-Apr-2025 08:08 ET (26-Apr-2025 12:08 GMT/UTC)
Research shows that instead of special protection against long COVID, vaccines kept children and adolescents from developing the condition by blocking COVID-19 infections in the first place
A vaccine under development at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work, detailed in a study published April 17 in the journal Cell Biomaterials, focuses on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks in wild birds and poultry and other mammals. The vaccine is step toward more potent, versatile and easy-to-produce vaccines that public health officials believe will be needed to counteract evolving bird flu strains that grow resistant to existing vaccines.
New bat cell lines and reagents help to study bat antiviral immune responses against hantaviruses and coronaviruses
Major reallocation of healthcare services during the COVID-19 pandemic meant that elective surgery in children with congenital heart disease (CHD) was significantly reduced, so that those needing urgent, lifesaving and emergency surgery could be treated. However, this prioritisation of the most severely ill children did not increase overall post-operative complications rates or death, a study led by the University of Bristol has shown.
https://doi.org/10.1016/j.apsb.2024.12.032
This new article publication from Acta Pharmaceutica Sinica B, discusses a retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years.
Virginia Tech researchers seek to understand the environmental factors that influence the distribution of hantavirus in rodent populations across the United States.
New USC research has found that COVID-19 therapies cause few serious side effects, based on an evaluation of the full spectrum of evidence available from U.S. biomedical science. The review, published in Open Forum Infectious Diseases, incorporated 54 studies spanning inpatient and outpatient treatment, clinical trials and observational research. Only investigations comparing COVID-19 therapy with standard care, placebo or no treatment were examined, so that effects of the disease itself could reasonably be excluded. No significant association with serious adverse events was found for oral antivirals such as Paxlovid. Evusheld and other monoclonal antibodies that bind to the coronavirus’s spike protein, previously administered intravenously in hospital but no longer authorized by the FDA due to their lack of effectiveness against COVID-19 variants, were not associated with serious adverse events. Actemra, an IV monoclonal antibody that works somewhat differently and is also known by the generic name tocilizumab, was associated with infection and low white blood cell counts in some studies. Transfusions of convalescent plasma — a blood product taken from recovered COVID-19 patients — were linked with higher risk of internal bleeding, infection and blood clots. The serious adverse events identified align with current product labeling.
The persistent higher rate of alcohol deaths in England since the pandemic in 2020 is an “acute crisis” requiring urgent action from government, according to a new study led by researchers at UCL and the University of Sheffield.
Cleveland Clinic virology researchers have found that a specific protein modification to the immune protein MDA5 is key to how our bodies detect and respond to viruses and viral replication.
The PNAS publication explains how two protein modifications activate MDA5, an essential immune protein, to sense invaders, limit viral replication and fight infections. This process is key to preventing outcomes like virus-induced heart inflammation.
This most recent publication builds on a body of work from the lab of Michaela Gack, PhD, scientific director of Cleveland Clinic’s Florida Research & Innovation Center, that seeks to improve our understanding of how our bodies detect viruses.
During the COVID-19 pandemic, tuberculosis (TB) mortality surged for the first time in two decades. While these increases were widely attributed to disruptions to TB services, such as diagnostic delays and treatment interruptions, a new study suggests that we may have overlooked the impact of food insecurity during pandemic lockdowns.
Using individual interviews and focus group discussions, researchers from Boston University, Jawaharlal Institute of Postgraduate Medical Education and Research, and London School of Hygiene and Tropical Medicine, found that 78% of households had no income, 67% resorted to distress financing to afford food, and 44% changed their diets—often by eating less or substituting less nutritious foods during the COVID-19 lockdowns in Southern India. Given the well-established link between undernutrition and TB progression, these findings raise important concerns about how food insecurity during crises may fuel TB-related deaths.